Traditionally, qPCR and RT-qPCR diagnostic assays include DNA/RNA extraction and purification steps to remove inhibitors from the PCR reactions, to meet the assay specificity and sensitivity. However, these steps are laborious, expensive, and time-consuming. To overcome this, Meridian has developed inhibitor tolerant mixes specifically for blood, saliva, urine, and stool. Meridian’s Direct Sample-Specific qPCR Mixes are the first mixes on the market overcoming the limitations of inhibitors inherent in the various clinical specimens, for ultimate assay sensitivity and specificity.

In this webinar our speakers will discuss:

The optimization strategy and methodology that have led to the development of these specimen-specific mixes, which have superior performance compared to other products on the market and enable faster, more sensitive, and cost-effective diagnostic assays.

Speakers:
Dr. Rachel Currier- Acting Team Leader, Research & Development
Dr. Thomas Fouqueau- Acting Team Leader, Research & Development

Moderator
Dr. Steve Hawkins, Product Marketing Manager